VAXIL BIO LTD (VXL.CA) Stock Price, Forecast & Analysis
TSX-V:VXL • CA92243L2066
VXL.CA Key Statistics, Chart & Performance
The current stock price of VXL.CA is 0.14 CAD. In the past year, price increased by 1300%.
VXL.CA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to VXL.CA. When comparing the yearly performance of all stocks, VXL.CA is one of the better performing stocks in the market, outperforming 99.2% of all stocks.
VXL.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VXL.CA. While VXL.CA has a great health rating, there are worries on its profitability.
VXL.CA Financial Highlights
Over the last trailing twelve months VXL.CA reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS increased by 22.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.37% | ||
| ROE | -10.49% | ||
| Debt/Equity | 0 |
VXL.CA Forecast & Estimates
VXL.CA Ownership
VXL.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC | N/A | 579.65M | ||
| EDT | SPECTRAL MEDICAL INC | N/A | 377.402M | ||
| HBP | HELIX BIOPHARMA CORP | N/A | 152.76M | ||
| MDNA | MEDICENNA THERAPEUTICS CORP | N/A | 71.733M | ||
| COV | COVALON TECHNOLOGIES LTD | 12.94 | 44.192M | ||
| BCT | BRIACELL THERAPEUTICS CORP | N/A | 39.513M | ||
| MBX | MICROBIX BIOSYSTEMS INC | 5.82 | 32.559M | ||
| RVX | RESVERLOGIX CORP | N/A | 28.756M | ||
| HEM | HEMOSTEMIX INC | N/A | 16.596M | ||
| MPH | MEDICURE INC | N/A | 11.693M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the TSX Venture Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About VXL.CA
Company Profile
Vaxil Bio Ltd. is an immunotherapy biotech company, which is engaged in the development of immunotherapies such as neoantigen-like peptide products, and antibodies to treat cancer and infectious diseases. The company is headquartered in Toronto, Ontario. The company went IPO on 2011-03-02. The firm is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The firm also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. The company has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. The company exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.
Company Info
VAXIL BIO LTD
559 Briar Hill Avenue,
TORONTO ONTARIO M5X 1A4 CA
CEO: David Goren
Employees: 0
VAXIL BIO LTD / VXL.CA FAQ
What does VAXIL BIO LTD do?
Vaxil Bio Ltd. is an immunotherapy biotech company, which is engaged in the development of immunotherapies such as neoantigen-like peptide products, and antibodies to treat cancer and infectious diseases. The company is headquartered in Toronto, Ontario. The company went IPO on 2011-03-02. The firm is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The firm also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. The company has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. The company exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.
What is the current price of VXL stock?
The current stock price of VXL.CA is 0.14 CAD.
Does VAXIL BIO LTD pay dividends?
VXL.CA does not pay a dividend.
What is the ChartMill rating of VAXIL BIO LTD stock?
VXL.CA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy VXL stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on VXL.CA.
What is the ownership structure of VAXIL BIO LTD (VXL.CA)?
You can find the ownership structure of VAXIL BIO LTD (VXL.CA) on the Ownership tab.